AI Article Synopsis
- The development of medicines for infectious diseases is a global health priority, particularly for chronic and emerging diseases.
- Innovative genetic technologies, like mRNA vaccines and CRISPR, show promise for effective treatment solutions.
- The review highlights advances in these therapies, their intersection with oncology, and the challenges of making them accessible and affordable for diverse populations.
Article Abstract
The development of prophylatic or therapeutic medicines for infectious diseases is one of the priorities for health organizations worldwide. Innovative solutions are required to achieve effective, safe, and accessible treatments for most if not all infectious diseases, particularly those that are chronic in nature or that emerge unexpectedly over time. Genetic technologies offer versatile possibilities to design therapies against pathogens. Recent developments such as mRNA vaccines, CRISPR gene editing, and immunotherapies provide unprecedented hope to achieve significant results in the field of infectious diseases. This review will focus on advances in this domain, showcasing the cross-fertilization with other fields ( oncology), and addressing some of the logistical and economic concerns important to consider when making these advances accessible to diverse populations around the world.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/hum.2023.123 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!